ECSP15048122A - Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b - Google Patents

Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b

Info

Publication number
ECSP15048122A
ECSP15048122A ECIEPI201548122A ECPI201548122A ECSP15048122A EC SP15048122 A ECSP15048122 A EC SP15048122A EC IEPI201548122 A ECIEPI201548122 A EC IEPI201548122A EC PI201548122 A ECPI201548122 A EC PI201548122A EC SP15048122 A ECSP15048122 A EC SP15048122A
Authority
EC
Ecuador
Prior art keywords
sulfamoylpyrrolamide
hepatitis
medicines
derivatives
treatment
Prior art date
Application number
ECIEPI201548122A
Other languages
English (en)
Inventor
Stefaan Julien Last
Geerwin Yvonne Paul Haché
Koen Vandyck
Wim Gaston Verschueren
Pierre Jean-Marie Bernard Raboisson
Gowan David Craig Mc
Geert Rombouts
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of ECSP15048122A publication Critical patent/ECSP15048122A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Inhibidores de la replicación del VHB de Fórmula (ID) (ver anexo) que incluyen las formas estereoquímicamente isoméricas y sales, hidratos y solvatos de estos, donde X, Ra-Rd y R4-R6 tienen los significados que se definen en la presente. La presente invención también se refiere a procesos para preparar dichos compuestos, a composiciones farmacéuticas que los contienen y a su uso, solo o combinado con otros inhibidores del VHB, en la terapia contra el VHB.
ECIEPI201548122A 2013-05-17 2015-11-17 Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b ECSP15048122A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP13168291 2013-05-17
EP13175181 2013-07-04
EP13182281 2013-08-29
EP13191209 2013-10-31
EP13198160 2013-12-18
EP14157900 2014-03-05

Publications (1)

Publication Number Publication Date
ECSP15048122A true ECSP15048122A (es) 2017-02-24

Family

ID=50884356

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201548122A ECSP15048122A (es) 2013-05-17 2015-11-17 Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b

Country Status (35)

Country Link
US (3) US9884818B2 (es)
EP (3) EP3121164B1 (es)
JP (3) JP6318238B2 (es)
KR (4) KR101867898B1 (es)
CN (2) CN110003076A (es)
AU (4) AU2014267220B2 (es)
BR (1) BR112015028461A2 (es)
CA (1) CA2909348C (es)
CL (1) CL2015003370A1 (es)
CY (2) CY1121391T1 (es)
DK (2) DK3121164T3 (es)
EA (1) EA037378B1 (es)
EC (1) ECSP15048122A (es)
ES (2) ES2699261T3 (es)
GT (1) GT201500312A (es)
HK (1) HK1218117A1 (es)
HR (2) HRP20181544T1 (es)
HU (2) HUE039997T2 (es)
IL (2) IL260597B (es)
JO (2) JO3603B1 (es)
LT (2) LT2997011T (es)
ME (1) ME03787B (es)
MX (3) MX2020011810A (es)
NI (1) NI201500161A (es)
PH (2) PH12015502579B1 (es)
PL (2) PL3121164T3 (es)
PT (2) PT3121164T (es)
RS (2) RS58140B1 (es)
SG (4) SG10201607293UA (es)
SI (2) SI3121164T1 (es)
TW (4) TW202126620A (es)
UA (1) UA117246C2 (es)
UY (1) UY35573A (es)
WO (1) WO2014184350A1 (es)
ZA (1) ZA201508443B (es)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
UA123256C2 (uk) 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
TWI719401B (zh) 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP6348978B2 (ja) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー グリオキサミド置換ピロールアミド誘導体およびｂ型肝炎を処置するための医薬品としてのその使用
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
CN110483484A (zh) * 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
RS59430B1 (sr) 2014-03-13 2019-11-29 Univ Indiana Res & Tech Corp Alosterni modulatori proteina jezgra hepatitisa b
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
AU2016297024B2 (en) 2015-07-22 2021-03-04 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
EP3402799B1 (en) * 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
JP7126947B2 (ja) * 2016-03-09 2022-08-29 エモリー ユニバーシティー 抗ウイルス剤によるｂ型肝炎ウイルスの排除
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
MX2018014377A (es) 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
SG11201810834WA (en) 2016-06-10 2018-12-28 Enanta Pharm Inc Hepatitis b antiviral agents
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018045144A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3512845A1 (en) 2016-09-15 2019-07-24 Assembly Biosciences, Inc. Hepatitis b core protein modulators
CR20190181A (es) 2016-10-14 2019-08-21 Prec Biosciences Inc Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
EA202190306A1 (ru) * 2016-11-11 2021-08-17 Новира Терапьютикс, Инк. Комбинации и способы, включающие ингибитор сборки капсида
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CN108341810B (zh) * 2017-01-23 2022-01-18 上海长森药业有限公司 环硫脲类化合物及其用途
WO2018133845A1 (zh) * 2017-01-23 2018-07-26 上海长森药业有限公司 硫脲类、脲类化合物及其用途
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
CN108456216B (zh) * 2017-02-22 2021-12-28 上海长森药业有限公司 磺酰肼类化合物及其用途
KR20190126102A (ko) 2017-03-02 2019-11-08 어셈블리 바이오사이언시스, 인크. 시클릭 술파미드 화합물 및 그의 사용 방법
SG11201908569QA (en) 2017-03-21 2019-10-30 Arbutus Biopharma Corp Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108794487B (zh) * 2017-05-04 2020-11-10 上海长森药业有限公司 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019154343A1 (zh) * 2018-02-09 2019-08-15 正大天晴药业集团股份有限公司 衣壳蛋白装配抑制剂、其药物组合物和用途
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
SG11202009150RA (en) 2018-03-30 2020-10-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US11459296B2 (en) 2018-05-16 2022-10-04 Infex Therapeutics Limited Antibacterial compounds
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
BR112021005091A2 (pt) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
CN113195055A (zh) 2018-10-22 2021-07-30 组装生物科学股份有限公司 用于hbv治疗的5元杂芳基甲酰胺化合物
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
EA202092159A1 (ru) 2019-01-25 2020-12-15 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210137518A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
CA3132095A1 (en) 2019-03-13 2020-09-17 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator solid formulation
MX2021011144A (es) 2019-03-18 2022-01-18 Enanta Pharm Inc Derivados de las benzodiazepinas como inhibidores del vsr.
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
AU2020259482A1 (en) 2019-04-18 2021-10-14 Janssen Pharmaceuticals, Inc. Combination therapy for treating Hepatitis B Virus infection
TW202106294A (zh) 2019-04-18 2021-02-16 美商健生醫藥公司 用於治療ｂ型肝炎病毒感染的組合療法（一）
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
KR20220043931A (ko) 2019-05-24 2022-04-05 어셈블리 바이오사이언시스, 인크. Hbv의 치료를 위한 제약 조성물
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020255013A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
US20220305116A1 (en) 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CA3153358A1 (en) * 2019-09-04 2021-03-11 Taigen Biotechnology Co., Ltd. Hepatitis b antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2022003984A (es) 2019-10-04 2022-07-27 Enanta Pharm Inc Compuestos heterociclicos antivirales.
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2021160617A1 (en) * 2020-02-11 2021-08-19 Irbm S.P.A. Spirocyclic inhibitors of hepatitis b virus
WO2021170741A1 (en) 2020-02-27 2021-09-02 Janssen Sciences Ireland Unlimited Company Treatment of hbv
TW202146011A (zh) 2020-03-05 2021-12-16 美商詹森藥物公司 治療b型肝炎病毒感染之組合療法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
US20230295096A1 (en) 2020-04-22 2023-09-21 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
KR20230005881A (ko) 2020-04-22 2023-01-10 어셈블리 바이오사이언시스, 인크. Hbv의 치료를 위한 5원 헤테로아릴 카르복스아미드 화합물
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
PE20230779A1 (es) 2020-08-07 2023-05-09 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2022206879A1 (zh) * 2021-03-31 2022-10-06 苏州晶云药物科技股份有限公司 氨磺酰基吡咯酰胺类化合物的晶型及其制备方法
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023164183A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
EP0135545A1 (en) 1983-02-19 1985-04-03 Beecham Group Plc Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (ja) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd ４，５−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤
IN164880B (es) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (en) 1987-03-13 1997-07-29 Rikuo Nasu Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
AU2534295A (en) 1994-05-27 1995-12-21 James Black Foundation Limited Gastrin and cck antagonists
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
JP2000512646A (ja) 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７受容体アンタゴニストとしてのスルホンアミド誘導体
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
WO1999048492A1 (fr) 1998-03-26 1999-09-30 Japan Tobacco Inc. Derives d'amide et antagonistes de nociceptine
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
BR0007527B1 (pt) 1999-01-15 2011-12-27 fenilfenantridinas com atividade inibitària de pde-iv, seu uso, bem como medicamento compreendendo as mesmas.
WO2001005390A2 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
ATE382351T1 (de) 1999-08-10 2008-01-15 Univ Oxford Langkettige n-alkyl verbindungen und deren oxa- derivate zur verwendung als anitvirale mittel
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
AU2882801A (en) 2000-01-28 2001-08-07 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
CN1247582C (zh) 2000-12-27 2006-03-29 大日本住友制药株式会社 新的碳代青霉烯化合物
AU2002248418A1 (en) 2001-02-09 2002-08-28 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
CN1243735C (zh) 2001-04-19 2006-03-01 卫材株式会社 2－亚氨基吡咯烷衍生物
SE0102315D0 (sv) * 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (de) 2001-07-25 2003-02-13 Degussa Verfahren zur Herstellung von modifiziertem Ruß
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
JP2005514366A (ja) 2001-11-20 2005-05-19 イーライ・リリー・アンド・カンパニー ３−置換オキシインドールβ３アゴニスト
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
CA2487891A1 (en) 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
CN1678311A (zh) 2002-06-27 2005-10-05 诺沃挪第克公司 用作治疗剂的芳基羰基衍生物
WO2004011427A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
JP4399862B2 (ja) 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
US7504426B2 (en) 2002-09-06 2009-03-17 Janssen Pharmaceutica N.V. Heterocyclic compounds
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
ES2378620T3 (es) 2003-03-27 2012-04-16 Cytokinetics, Inc. Sulfonamidas para el tratamiento de insuficiencia cardiaca congestiva, sus composiciones y usos.
JP2006525366A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環式カルボン酸置換基
WO2004100947A2 (en) 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
MXPA05012268A (es) 2003-05-13 2006-02-10 Schering Corp N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US8404747B2 (en) 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
WO2005115374A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for therapeutic use
WO2006002133A1 (en) 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
PL1773768T3 (pl) 2004-07-30 2019-03-29 Exelixis, Inc. Pochodne pirolu jako środki farmaceutyczne
BRPI0514691A (pt) 2004-08-31 2008-06-17 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
DE102004042441A1 (de) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2005295788A1 (en) 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
US8008335B2 (en) 2004-10-19 2011-08-30 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
AR054183A1 (es) 2004-12-22 2007-06-06 Astrazeneca Ab Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
FI117653B (fi) 2005-02-21 2006-12-29 Eigenor Oy Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
RS51470B (en) 2005-09-16 2011-04-30 Arrow Therapeutics Limited BIPHENYL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HEPATITIS C
CA2633541A1 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
MX2008008340A (es) 2005-12-21 2008-09-03 Schering Corp Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
EP1981849A1 (en) 2005-12-29 2008-10-22 LEK Pharmaceuticals D.D. Heterocyclic compounds
EP2019830A4 (en) 2006-05-04 2011-01-19 Inst Hepatitis & Virus Res INHIBITORS OF THE SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR THE TREATMENT OF A CHRONIC HEPATITIS VIRUS
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
US20100016310A1 (en) 2006-08-17 2010-01-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
US20100113421A1 (en) 2006-10-06 2010-05-06 Williams Theresa M Non-nucleoside reverse transcriptase inhibitors
EP2091527B1 (en) 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
JP2008184403A (ja) 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
BRPI0811516A2 (pt) 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase
CL2008001631A1 (es) * 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
BRPI0815038A2 (pt) 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
CN101429166B (zh) 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2009146013A1 (en) 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
AU2009239116B2 (en) 2008-04-24 2013-05-30 Msd K.K. Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
WO2009158587A1 (en) 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
EP2321268A2 (en) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryl aminotetralines
WO2010027996A1 (en) 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
UY32251A (es) 2008-11-20 2010-05-31 Glaxosmithkline Llc Compuestos quimicos
WO2010065782A1 (en) 2008-12-04 2010-06-10 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010123139A1 (ja) 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
JP2012527414A (ja) 2009-05-19 2012-11-08 バイエル・クロップサイエンス・アーゲー 殺虫性アリールピロリン
CA3080983C (en) 2009-05-27 2023-02-28 Pct Therapeutics, Inc. Method of inhibiting and reducing a viral infection
KR20120049852A (ko) 2009-06-30 2012-05-17 시가 테크놀로지스, 인크. 뎅기 바이러스 감염의 치료 및 예방
CA2689707A1 (en) * 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
WO2011058766A1 (en) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
CN102093320B (zh) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
WO2011088561A1 (en) 2010-01-20 2011-07-28 University Of Manitoba Anti-viral compounds and compositions
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
WO2011112191A1 (en) 2010-03-11 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
PT2566327T (pt) 2010-05-07 2017-05-26 Glaxosmithkline Llc Indoles
WO2011155898A1 (en) 2010-06-11 2011-12-15 Wadell Goeran New antiviral compounds
US20130142827A1 (en) 2010-06-25 2013-06-06 Philadelphia Health & Education Corporation D/B/A Induction of immune response
CN103052406A (zh) 2010-07-19 2013-04-17 印斯拜尔药品股份有限公司 双官能rho激酶抑制剂化合物、组合物及应用
JP2013536178A (ja) 2010-07-26 2013-09-19 ニューロセラピューティクス ファーマ， インコーポレイテッド アリールスルホンアミド誘導体、組成物、および使用方法
BR112013001015A2 (pt) 2010-07-27 2016-05-24 Inspire Pharmaceuticals Inc método por tratar doenças oftálmicas que usam compostos de inibidor de cinase em formas de prodrug
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
WO2012047856A2 (en) 2010-10-04 2012-04-12 Institute For Hepatitis And Virus Research Novel inhibitors of secretion of hepatitis b virus antigens
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (es) 2011-02-28 2011-04-13 Univ Aberdeen
RS57758B1 (sr) 2011-04-08 2018-12-31 Janssen Sciences Ireland Uc Pirimidinski derivati za tretman viralnih infekcija
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013006394A1 (en) * 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
UY34566A (es) 2012-01-06 2013-07-31 Janssen R & D Ireland 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
NZ631419A (en) 2012-02-29 2017-03-31 Baruch S Blumberg Inst Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use
WO2013144129A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
BR112014029697A2 (pt) 2012-06-01 2017-08-08 Baruch S Blumberg Inst método para modular a transcrição de cccdna de hepatite b em um indivíduo, método para modular dna circular covalentemente fechado de vírus da hepatite b e composto
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
PL2890683T3 (pl) 2012-08-28 2017-06-30 Janssen Sciences Ireland Uc Pochodne skondensowanego bicyklicznego sulfamylu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
UA123256C2 (uk) * 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b
MA37942B1 (fr) 2012-09-10 2020-01-31 Hoffmann La Roche Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
BR112015015584A2 (pt) 2012-12-27 2017-12-12 Baruch S Blumberg Inst novos agentes antivirais contra infecção por hbv
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
UA114950C2 (uk) 2013-02-28 2017-08-28 Ейсей Р Енд Д Менеджмент Ко., Лтд. ТЕТРАГІДРОІМІДАЗО[1,5-d][1,4]ОКСАЗЕПІНОВА ПОХІДНА
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US9266904B2 (en) 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9688681B2 (en) 2013-05-28 2017-06-27 Bayer Cropscience Aktiengesellschaft Heterocyclic compounds as pest control agents
WO2014191726A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
JP6348978B2 (ja) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー グリオキサミド置換ピロールアミド誘導体およびｂ型肝炎を処置するための医薬品としてのその使用
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
ES2777248T3 (es) 2013-11-14 2020-08-04 Novira Therapeutics Inc Derivados de azepano y métodos de tratar infecciones por hepatitis B
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
BR112016017808B1 (pt) 2014-01-31 2022-07-12 Cognition Therapeutics, Inc Composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
DK3114128T3 (en) 2014-03-07 2019-03-25 Hoffmann La Roche New 6-fused heteroaryld dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
RS59430B1 (sr) 2014-03-13 2019-11-29 Univ Indiana Res & Tech Corp Alosterni modulatori proteina jezgra hepatitisa b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
EP3150600B1 (en) 2014-05-30 2018-06-27 Qilu Pharmaceutical Co., Ltd. Dihydropyrimido loop derivative as hbv inhibitor
CA2969557A1 (en) 2014-12-02 2016-06-09 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
US9518057B2 (en) 2014-12-30 2016-12-13 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
EP3283472B1 (en) 2015-04-17 2021-04-14 Indiana University Research & Technology Corporation Hepatitis b viral assembly effectors
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CN109251212A (zh) 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
SI3121164T1 (sl) 2020-06-30
UA117246C2 (uk) 2018-07-10
CN105452220A (zh) 2016-03-30
JP2020117530A (ja) 2020-08-06
CY1121391T1 (el) 2020-05-29
ES2699261T3 (es) 2019-02-08
EA037378B1 (ru) 2021-03-22
CA2909348C (en) 2019-01-08
CN110003076A (zh) 2019-07-12
MX366722B (es) 2019-07-22
ES2787704T3 (es) 2020-10-16
PL3121164T3 (pl) 2020-07-27
KR102055639B1 (ko) 2019-12-13
DK2997011T3 (en) 2018-12-17
EP2997011A1 (en) 2016-03-23
DK3121164T3 (da) 2020-05-11
SG10201607294SA (en) 2016-10-28
KR20190139328A (ko) 2019-12-17
RS58140B1 (sr) 2019-02-28
PL2997011T3 (pl) 2019-03-29
AU2014267220B2 (en) 2017-09-28
RS60285B1 (sr) 2020-06-30
JP6318238B2 (ja) 2018-04-25
LT3121164T (lt) 2020-08-10
US20160115125A1 (en) 2016-04-28
JO3583B1 (ar) 2020-07-05
PH12018501812A1 (en) 2019-11-18
MX2015015770A (es) 2016-03-11
EA201592200A1 (ru) 2016-03-31
KR20210025712A (ko) 2021-03-09
ME03787B (me) 2021-04-20
MX2019008585A (es) 2019-09-19
NI201500161A (es) 2016-01-06
GT201500312A (es) 2018-01-17
US9884818B2 (en) 2018-02-06
IL264541A (en) 2019-02-28
SG10202002604PA (en) 2020-05-28
IL260597B (en) 2019-03-31
US20180141905A1 (en) 2018-05-24
HUE050236T2 (hu) 2020-11-30
AU2019236657B2 (en) 2021-05-20
HUE039997T2 (hu) 2019-02-28
AU2017276170A1 (en) 2018-01-18
KR102223535B1 (ko) 2021-03-08
TW202017903A (zh) 2020-05-16
US10457638B2 (en) 2019-10-29
AU2014267220A1 (en) 2015-11-05
ZA201508443B (en) 2020-08-26
SG11201509428PA (en) 2015-12-30
SI2997011T1 (sl) 2018-11-30
HRP20181544T1 (hr) 2018-11-30
TW201522305A (zh) 2015-06-16
TW201908289A (zh) 2019-03-01
EP3121164A1 (en) 2017-01-25
NZ713201A (en) 2021-03-26
CL2015003370A1 (es) 2016-05-27
AU2021206827A1 (en) 2021-08-12
SG10201607293UA (en) 2016-10-28
KR101867898B1 (ko) 2018-06-15
LT2997011T (lt) 2018-10-25
PT2997011T (pt) 2018-11-30
UY35573A (es) 2014-11-28
HK1218117A1 (zh) 2017-02-03
EP2997011B1 (en) 2018-08-29
EP3121164B1 (en) 2020-02-19
JP2018118990A (ja) 2018-08-02
TWI684586B (zh) 2020-02-11
BR112015028461A2 (pt) 2017-07-25
TWI651300B (zh) 2019-02-21
KR20180066279A (ko) 2018-06-18
TWI733288B (zh) 2021-07-11
CN105452220B (zh) 2019-01-25
IL264541B (en) 2019-09-26
PT3121164T (pt) 2020-05-12
CY1123298T1 (el) 2021-12-31
EP3594204A1 (en) 2020-01-15
HRP20200648T1 (hr) 2020-07-10
AU2019236657A1 (en) 2019-10-17
US20200039931A1 (en) 2020-02-06
JP2016518434A (ja) 2016-06-23
AU2017276170B2 (en) 2019-07-11
PH12015502579A1 (en) 2016-02-29
WO2014184350A1 (en) 2014-11-20
JO3603B1 (ar) 2020-07-05
TW202126620A (zh) 2021-07-16
PH12015502579B1 (en) 2016-02-29
KR20160008574A (ko) 2016-01-22
CA2909348A1 (en) 2014-11-20
MX2020011810A (es) 2021-10-21

Similar Documents

Publication Publication Date Title
ECSP15048122A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20160275A (es) Derivados del sulphamoylpyrrolamide y uso como medicamento para el tratamiento de la hepatitis b
ECSP15007335A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CR20170478A (es) Compuestos novedosos
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
MX2015011229A (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
MX2015015771A (es) Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
PE20151979A1 (es) Compuestos quimicos
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CR20150584A (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
BR112016028017A2 (pt) Inibidor de quinase alk e método de preparação e usos do mesmo
CR20160175A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
EA202092842A3 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
CR20150060A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.